Shorter duration of first-line chemotherapy reflects poorer outcomes in patients with HER2-negative advanced breast cancer: a multicenter retrospective study

Abstract Post-progression survival affects overall survival (OS) in patients with HER2-negative advanced breast cancer (HER2-ABC); thus, the optimal choice of first-line chemotherapy (1LCT) remains controversial. We investigated patients with HER2-ABC focusing on their sensitivity to 1LCT. We retros...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Shogo Nakamoto, Junichiro Watanabe, Shoichiro Ohtani, Satoshi Morita, Masahiko Ikeda
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/86285e9b6b9e4519a0e2732749a6ffd2
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:86285e9b6b9e4519a0e2732749a6ffd2
record_format	dspace
spelling	oai:doaj.org-article:86285e9b6b9e4519a0e2732749a6ffd22021-11-08T10:47:35ZShorter duration of first-line chemotherapy reflects poorer outcomes in patients with HER2-negative advanced breast cancer: a multicenter retrospective study10.1038/s41598-021-00711-x2045-2322https://doaj.org/article/86285e9b6b9e4519a0e2732749a6ffd22021-11-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-00711-xhttps://doaj.org/toc/2045-2322Abstract Post-progression survival affects overall survival (OS) in patients with HER2-negative advanced breast cancer (HER2-ABC); thus, the optimal choice of first-line chemotherapy (1LCT) remains controversial. We investigated patients with HER2-ABC focusing on their sensitivity to 1LCT. We retrospectively analyzed patients with HER2-ABC who received 1LCT between January 2011 and December 2016 in three participating institutions. We identified 149 patients in the shorter and 152 patients in the longer time to treatment failure (TTF) groups. The median OS was significantly longer in the longer TTF group (hazard ratio [HR] 0.44, P < 0.001, log-rank). In the shorter TTF group, OS of patients who received paclitaxel plus bevacizumab (PB) therapy was significantly inferior to that of those who received chemotherapy other than PB (HR 2.57, P < 0.001, log-rank), and subsequent eribulin therapy significantly improved OS from 1LCT initiation (Wilcoxon P < 0.001); multivariate analyses showed that 1LCT PB therapy was an independent risk factor for poorer OS (HR 2.05, P = 0.003), while subsequent eribulin therapy was an independent prognostic factor for better OS (HR 0.56, P = 0.004). OS was significantly poorer in patients with HER2-ABC with a shorter duration of 1LCT, including PB therapy, while subsequent eribulin therapy improved OS.Shogo NakamotoJunichiro WatanabeShoichiro OhtaniSatoshi MoritaMasahiko IkedaNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-9 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Shogo Nakamoto Junichiro Watanabe Shoichiro Ohtani Satoshi Morita Masahiko Ikeda Shorter duration of first-line chemotherapy reflects poorer outcomes in patients with HER2-negative advanced breast cancer: a multicenter retrospective study
description	Abstract Post-progression survival affects overall survival (OS) in patients with HER2-negative advanced breast cancer (HER2-ABC); thus, the optimal choice of first-line chemotherapy (1LCT) remains controversial. We investigated patients with HER2-ABC focusing on their sensitivity to 1LCT. We retrospectively analyzed patients with HER2-ABC who received 1LCT between January 2011 and December 2016 in three participating institutions. We identified 149 patients in the shorter and 152 patients in the longer time to treatment failure (TTF) groups. The median OS was significantly longer in the longer TTF group (hazard ratio [HR] 0.44, P < 0.001, log-rank). In the shorter TTF group, OS of patients who received paclitaxel plus bevacizumab (PB) therapy was significantly inferior to that of those who received chemotherapy other than PB (HR 2.57, P < 0.001, log-rank), and subsequent eribulin therapy significantly improved OS from 1LCT initiation (Wilcoxon P < 0.001); multivariate analyses showed that 1LCT PB therapy was an independent risk factor for poorer OS (HR 2.05, P = 0.003), while subsequent eribulin therapy was an independent prognostic factor for better OS (HR 0.56, P = 0.004). OS was significantly poorer in patients with HER2-ABC with a shorter duration of 1LCT, including PB therapy, while subsequent eribulin therapy improved OS.
format	article
author	Shogo Nakamoto Junichiro Watanabe Shoichiro Ohtani Satoshi Morita Masahiko Ikeda
author_facet	Shogo Nakamoto Junichiro Watanabe Shoichiro Ohtani Satoshi Morita Masahiko Ikeda
author_sort	Shogo Nakamoto
title	Shorter duration of first-line chemotherapy reflects poorer outcomes in patients with HER2-negative advanced breast cancer: a multicenter retrospective study
title_short	Shorter duration of first-line chemotherapy reflects poorer outcomes in patients with HER2-negative advanced breast cancer: a multicenter retrospective study
title_full	Shorter duration of first-line chemotherapy reflects poorer outcomes in patients with HER2-negative advanced breast cancer: a multicenter retrospective study
title_fullStr	Shorter duration of first-line chemotherapy reflects poorer outcomes in patients with HER2-negative advanced breast cancer: a multicenter retrospective study
title_full_unstemmed	Shorter duration of first-line chemotherapy reflects poorer outcomes in patients with HER2-negative advanced breast cancer: a multicenter retrospective study
title_sort	shorter duration of first-line chemotherapy reflects poorer outcomes in patients with her2-negative advanced breast cancer: a multicenter retrospective study
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/86285e9b6b9e4519a0e2732749a6ffd2
work_keys_str_mv	AT shogonakamoto shorterdurationoffirstlinechemotherapyreflectspooreroutcomesinpatientswithher2negativeadvancedbreastcanceramulticenterretrospectivestudy AT junichirowatanabe shorterdurationoffirstlinechemotherapyreflectspooreroutcomesinpatientswithher2negativeadvancedbreastcanceramulticenterretrospectivestudy AT shoichiroohtani shorterdurationoffirstlinechemotherapyreflectspooreroutcomesinpatientswithher2negativeadvancedbreastcanceramulticenterretrospectivestudy AT satoshimorita shorterdurationoffirstlinechemotherapyreflectspooreroutcomesinpatientswithher2negativeadvancedbreastcanceramulticenterretrospectivestudy AT masahikoikeda shorterdurationoffirstlinechemotherapyreflectspooreroutcomesinpatientswithher2negativeadvancedbreastcanceramulticenterretrospectivestudy
_version_	1718442634515578880

Shorter duration of first-line chemotherapy reflects poorer outcomes in patients with HER2-negative advanced breast cancer: a multicenter retrospective study

Ejemplares similares